News & Updates

Ondansetron shows potential in irritable bowel syndrome with diarrhoea
Ondansetron shows potential in irritable bowel syndrome with diarrhoea
27 Mar 2023

A study on titrated ondansetron for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) has fallen short of meeting the endpoint due to being underpowered. However, when data from this study and two others were pooled in a meta-analysis, ondansetron appears to yield significant improvements in the composite endpoint set by the Food and Drug Administration (FDA), namely stool consistency and urgency.

Ondansetron shows potential in irritable bowel syndrome with diarrhoea
27 Mar 2023
Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial
Perfluorohexyloctane eye drops for dry eye disease impresses in phase III trial
25 Mar 2023
Long-term dupilumab proven safe, effective in children with asthma
Long-term dupilumab proven safe, effective in children with asthma
24 Mar 2023 byStephen Padilla

Long-term treatment with dupilumab is well tolerated, and its efficacy in children with uncontrolled, moderate-to-severe asthma as seen in the VOYAGE study is consistent, according to the EXCURSION open-label extension study. In addition, patients who switched from placebo to dupilumab has improved rapid lung function.

Long-term dupilumab proven safe, effective in children with asthma
24 Mar 2023